Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for Stage III Colorectal Cancer
NCT06197425Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- May 2026
- Primary completion
- May 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of FOLFIRI and trifluridine + tipiracil in colorectal cancer (CRC) (4 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Time to Recurrence. Started May 2026; status: recruiting.
02
Drugs
FOLFIRItrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06197425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06197425.